You are here

Novartis

Novartis gets FDA breakthrough therapy status for ligelizumab to treat chronic spontaneous urticaria

Novartis gets FDA breakthrough therapy status for ligelizumab to treat chronic spontaneous urticaria

Pharmaceutical Business Review

breakthrough therapy

chronic spontaneous urticaria

Flag link:

JPM: Novartis CMO Tsai on how the pandemic is changing the face of biopharma R&D, how pharma works

JPM: Novartis CMO Tsai on how the pandemic is changing the face of biopharma R&D, how pharma works

Fierce Biotech

Flag link:

BeiGene, Novartis in pact to develop tislelizumab for cancer settings

BeiGene, Novartis in pact to develop tislelizumab for cancer settings

Seeking Alpha

drug development

Flag link:

Lilly, Amgen and more back advocacy group's push to double migraine research dollars

Lilly, Amgen and more back advocacy group's push to double migraine research dollars

Fierce Pharma

Teva Pharmaceutical

Flag link:

FDA Refuses to Approve Novartis' $9.7 Billion Cholesterol Drug for Now

FDA Refuses to Approve Novartis' $9.7 Billion Cholesterol Drug for Now

Motley Fool

complete response letter

Flag link:

Novartis acquires a small biotech and its trio of brain drugs

Novartis acquires a small biotech and its trio of brain drugs

BioPharma Dive

Flag link:

Amgen and Novartis tap TV host to jump-start migraine conversations—and fuel understanding

Amgen and Novartis tap TV host to jump-start migraine conversations—and fuel understanding

Fierce Pharma

celebrity endorsements

Flag link:

Novartis' heart failure med Entresto wins FDA panel backing for bigger patient group—but just how much bigger?

Novartis' heart failure med Entresto wins FDA panel backing for bigger patient group—but just how much bigger?

Fierce Pharma

heart failure with preserved ejection fraction

Flag link:

Roche's MS blockbuster Ocrevus, facing new Novartis competition, scores FDA nod for more-convenient infusion

Roche's MS blockbuster Ocrevus, facing new Novartis competition, scores FDA nod for more-convenient infusion

Fierce Pharma

multiple sclerosis

Flag link:

Novartis raises the temp on Eylea rivalry with head-to-head trial win for Beovu in diabetic macular edema

Novartis raises the temp on Eylea rivalry with head-to-head trial win for Beovu in diabetic macular edema

Endpoints

diabetic macular edema

Flag link:

Novartis/Incyte draw blank with Jakafi in COVID-19

Novartis/Incyte draw blank with Jakafi in COVID-19

Pharmaforum

clinical trials

Flag link:

Novartis’ $9.7B PCSK9 drug nabs first OK — now comes the challenge of finding a market

Novartis’ $9.7B PCSK9 drug nabs first OK — now comes the challenge of finding a market

Endpoints

Flag link:

SABCS: Novartis touts Kisqali's 5-year breast cancer survival, advantage over Pfizer's Ibrance

SABCS: Novartis touts Kisqali's 5-year breast cancer survival, advantage over Pfizer's Ibrance

Fierce Pharma

Flag link:

ASH20: Out to shake up CML once again, Novartis lays out head-to-head between third-gen Gleevec scion and Pfizer rival

ASH20: Out to shake up CML once again, Novartis lays out head-to-head between third-gen Gleevec scion and Pfizer rival

Endpoints

Flag link:

Novartis signs ophthalmology AI deal with RetinAI

Novartis signs ophthalmology AI deal with RetinAI

Pharmaforum

Flag link:

ASH: Novartis makes its Kymriah case in follicular lymphoma, but another Gilead showdown awaits

ASH: Novartis makes its Kymriah case in follicular lymphoma, but another Gilead showdown awaits

Fierce Pharma

follicular lymphoma

clinical trials

Flag link:

Novartis’s big wager on RNAi approaches the finish line

Novartis’s big wager on RNAi approaches the finish line

EP Vantage

Flag link:

Novartis taps smartpatient for app to support wet AMD patients

Novartis taps smartpatient for app to support wet AMD patients

Pharmaforum

wet age-related macular degeneration

digital therapeutics

Flag link:

Novartis Inks $1.35 Billion Deal with Mesoblast for Remestemcel-L for COVID-19 ARDS

Novartis Inks $1.35 Billion Deal with Mesoblast for Remestemcel-L for COVID-19 ARDS

BioSpace

clinical trials

Flag link:

FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar

FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar

Pharmaforum

Samsung Bioepis

Flag link:

Pages